title: Are calcium channel blockers protective against first-dose reactions to OKT3?
authors.affiliation: Department of Medicine, Yale University School of Medicine, New Haven, CT 06510.
authors.forename: E A
authors.initials: EA
authors.lastname: Richard
authors.forename: M I
authors.initials: MI
authors.lastname: Lorber
authors.forename: W H
authors.initials: WH
authors.lastname: Marks
authors.forename: M J
authors.initials: MJ
authors.lastname: Bia
mesh_terms: D000328:Adult; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D016853:Muromonab-CD3 / Q000009:adverse effects*
chemical_list: D002121:Calcium Channel Blockers; D016853:Muromonab-CD3